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Hepatitis C virus (HCV) remains a major global health burden, with approximately 150 
million people persistently infected. Chronically infected individuals are at increased risk for 
severe progressive liver disease, including cirrhosis and hepatocellular carcinoma. 
Importantly, the burden of HCV-associated disease will likely remain substantial in the era 
of oral direct-acting antivirals, even in high-resource countries such as the United States.1 
The risk for hepatocellular carcinoma can persist after viral cure, in particular when fibrosis 
is already established.2 HCV interacts with an extensive network of host factors during 
infection of hepatocytes, which may provide novel targets for host-directed antivirals. 
Furthermore, a comprehensive identification of HCV host dependencies is crucial to better 
understand the pathogenesis of HCV-induced liver disease biology and to identify strategies 
for the prevention of hepatocellular carcinoma. In this issue of Gastroenterology, Zhang et 
al3 characterize the role of SMAD6 in the regulation of HCV entry and uncover a new role 
for inhibitory SMADs (I-SMADs) in viral pathogenesis.
HCV entry is a highly coordinated process, requiring interaction with a number of cellular 
factors. After binding to heparan sulfate proteoglycans (HSPGs) and lipoprotein receptors, 
including low-density lipoprotein receptor and scavenger receptor class B1 type I, viral 
particles are endocytosed and fuse in early endosomes. Although several host proteins have 
been identified as regulatory factors, the detailed regulation of the HCV entry process is only 
partially understood.4 Zhang et al3 follow up on their previous identification of SMAD6 as 
an HCV host factor.5 Transcriptomics analysis revealed that silencing of SMAD6 decreased 
the expression of HSPGs, with a corresponding reduction in cell surface expression of 
heparan sulfate.3 Furthermore, SMAD6 knockdown decreased expression of cholesterol 
uptake receptors and HCV entry factors, including low-density lipoprotein receptor and 
scavenger receptor class B1 type I. In contrast, exogenous expression of SMAD6 was shown 
to up-regulate the expression of HSPGs and cholesterol uptake receptors.3 By modulating 
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the expression of viral entry factors, SMAD6 regulates the ability of HCV to infect cells 
(Figure 1).
SMAD6 is an inhibitory I-SMAD within the broader family of SMAD proteins. These 
proteins play important roles in signal transduction, particularly in regulating the 
transforming growth factor (TGF)-β pathway. Whereas the receptor-regulated SMADs, 
including SMAD2,SMAD3,SMAD4, and SMAD5, positively regulate TGF-β signaling, the 
I-SMADs SMAD6 and SMAD7 act as antagonists of the this pathway. I-SMADs also act as 
transcriptional co-activators, given their role in activating transcription of genes encoding 
HSPGs and cholesterol uptake receptors.3 Because I-SMADs are induced by the bone 
morphogenetic protein (BMP)/TGF-β signaling pathway, the cytokines BMP6 and BMP7 
induce expression of I-SMADs to increase HCV entry factor expression.3 Interestingly, 
HSPGs themselves are BMP co-receptors and contribute to the regulation of BMP/TGF-β 
signaling.6 This study, therefore, opens avenues for further studies to dissect the interplay 
between I-SMADs, BMPs, and HSPGs in the context of chronic HCV infection, which may 
identify novel antiviral or chemo-preventive strategies for HCV-induced liver disease. For 
example, BMP6 inhibits hepatic fibrosis in nonalcoholic fatty liver disease7 and may 
represent a promising therapeutic target. Interestingly, SMAD7 was proposed previously as a 
candidate for novel therapeutic approaches to limit TGF-β–mediated fibrogenesis arising 
during chronic hepatitis B virus infection8 and may provide a strategy to broadly ameliorate 
the fibrosis caused by multiple etiologies in human hepatic diseases.
HCV infection up-regulates the expression of I-SMADs in hepatocytes via activation of 
nuclear factor-κB,3 thereby increasing expression of HSPGs and cholesterol uptake 
receptors (Figure 1). Increased I-SMAD and HSPG messenger RNA expression was 
observed in HCV-infected liver biopsies, 3 confirming relevance in patients. Increased 
cholesterol uptake into infected cells likely enhances viral replication and assembly steps, 
given the critical roles of cholesterol in the viral life cycle.9 The modulation of signaling 
pathways or metabolic processes impacted by HSPGs may also contribute to enhanced viral 
replication. Furthermore, increased HSPG expression on the surface of infected hepatocytes 
may concentrate the virus in the liver microenvironment to facilitate the infection of 
neighboring cells.
The HCV-induced increase in I-SMAD expression likely has profound implications for HCV 
disease biology and pathogenesis, given the multiple roles of I-SMADs in regulating HSPG 
expression, cholesterol uptake, and TGF-β signaling. HSPGs play key roles in cell adhesion 
and migration, as well as in binding to cytokines and growth factors and regulating growth 
factor receptors to modulate downstream signal transduction.10 The HCV-induced I-SMAD–
mediated up-regulation of HSPG expression may well impact hepatocyte proliferation or 
migration, contributing to hepatocarcinogenesis or migration of cancerous cells. Similarly, 
aberrant regulation of the TGF-β pathway may impact cellular proliferation, differentiation, 
death, and migration in the liver, as TGF-β and other growth factors regulate these processes 
to maintain tissue homeostasis. It would be interesting to evaluate potential correlations 
between HCV-induced modulation of I-SMAD–regulated processes and the severity of liver 
disease in chronically infected patients.
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Zhang et al3 now identify a new role for I-SMADs as regulators of lipid metabolism in the 
liver. By inducing the expression of HSPGs11 and lipoprotein uptake receptors, I-SMADs 
contribute to the uptake of cholesterol and lipids into the liver. In the context of HCV 
infection, this function of I-SMADs may contribute to steatosis. Furthermore, given the role 
of BMP6 as a regulator of iron uptake12 and the fact that iron metabolism seems to be 
dysregulated during chronic hepatitis C infection,13 I-SMADs and the BMP/TGF-β pathway 
suggest a link between iron homeostasis and lipid metabolism in HCV-infected cells. Further 
mechanistic studies are warranted, since they may provide targets to limit steatosis and iron 
accumulation in the liver of infected patients. Because the TGF-β pathway is also involved 
in inflammation and immune regulation, it would be interesting to further probe the roles of 
I-SMADs in HCV-induced inflammation, a key contributor to fibrosis.
Overall, Zhang et al3 identify a novel regulatory mechanism for HCV entry, with 
implications for HCV pathogenesis and liver disease. Modulation of the activity of I-
SMADs or related factors such as BMP6 could prevent HCV infection by modulation of 
entry factor expression. More importantly, these findings may provide novel perspectives to 
prevent or limit the development of HCV-induced liver disease to improve the outlook for 
chronically infected patients.
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Figure 1. 
Proposed role of I-SMADs during hepatitis C virus (HCV) infection according to Zhang et 
al.3 I-SMADs, induced by HCV infection, transcriptionally regulate expression of HCV 
entry factors, including HSPGs and cholesterol uptake receptors. HSPGs, heparan sulfate 
proteoglycans; SR-BI, scavenger receptor class B type I; LDLR, low density lipoprotein 
receptor; NF-κB, nuclear factor kappa B; TGF-β, transforming growth factor beta; I-
SMADs, inhibitory SMADs.
Colpitts and Baumert Page 5
Gastroenterology. Author manuscript; available in PMC 2017 February 17.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
